Blog
RSS FeedPosted by Michael Wonder on 04 Feb 2020
Interferon, Kaletra to get insurance benefit for new coronavirus treatment
4 February 2020 - The government said it would allow health insurance benefits for patients who received interferon or combo ...
Posted by Michael Wonder on 29 Jan 2020
‘Dupixent revolutionary atopic dermatitis drug to end lack of fundamental treatment’
29 January 2020 - Sanofi Genzyme exec stresses development of accurate pain index for patients. ...
Posted by Michael Wonder on 22 Jan 2020
Reimbursement for Repatha to expand treatment options for ASCVD patients
22 January 2020 - Amgen is set to expand treatment options for atherosclerotic cardiovascular disease patients with Repatha, a high-cholesterol treatment, ...
Posted by Michael Wonder on 19 Dec 2019
Regulatory agency expands cooperation with European counterparts
18 december 2019 - The Ministry of Food and Drug Safety said that it has signed multiple agreements with its ...
Posted by Michael Wonder on 04 Dec 2019
Drug makers strongly oppose post-approval evaluation
4 December 2019 - The pharmaceutical industry adamantly criticised the government’s plan to evaluate expensive anti-cancer therapies and orphan drugs, ...
Posted by Michael Wonder on 24 Oct 2019
Value assessment on anti-cancer drugs hotly discussed
24 October 2019 - Experts are raising the need to establish tools to calculate the value of new anticancer medicines ...
Posted by Michael Wonder on 14 Oct 2019
Sanofi to cover part of Dupixent cost for atopic dermatitis patients
11 October 2019 - Sanofi said it would run a program to support part of the cost of Dupixent, a ...
Posted by Michael Wonder on 02 Oct 2019
CDK4/6 inhibitor+fulvestrant combo nears getting benefit
2 October 2019 - The combination therapy of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor and fulvestrant for advanced or metastatic ...
Posted by Michael Wonder on 25 Sep 2019
'Xtandi emerges as convenient treatment option for prostate cancer patients'
25 September 2019 - Astellas Korea is strengthening its position in the local prostate cancer market with Xtandi, a hormone therapy ...
Posted by Michael Wonder on 16 Sep 2019
Lenvima to get benefit as first-line treatment of hepatocellular carcinoma
16 September 2019 - Lenvima (lenvatinib), a new liver cancer drug that arrived in a decade after Nexavar (sorafenib), is to ...
Posted by Michael Wonder on 27 Aug 2019
Pharmacists demand audit over Gliatilin’s insurance benefit
27 August 2019 - A pharmacists’ group demanded an audit against the Ministry of Health and Welfare and the Health ...
Posted by Michael Wonder on 06 Aug 2019
Health ministry to reimburse Novartis’ Revolade treating severe aplastic anaemia
1 August 2019 - Novartis Korea’s Revolade (eltrombopag olamine) will receive reimbursement for treating people with severe aplastic anaemia who ...
Posted by Michael Wonder on 29 Jul 2019
Takeda’s Zejula poised to change local ovarian cancer treatment market
29 July 2019 - Takeda’s Zejula (ingredient: niraparib) became eligible for an insurance benefit, according to the Health Insurance Review and ...
Posted by Michael Wonder on 27 Jul 2019
Pfizer's Besponsa, Takeda's Zejula likely to get insurance coverage
26 July 2019 - Pfizer's Besponsa, a B-cell lymphoblastic leukaemia treatment, and Takeda's Zejula, an ovarian cancer treatment, have passed ...
Posted by Michael Wonder on 18 Jul 2019
Two cancer immunotherapy makers face different situations in reimbursement talks
18 July 2019 - MSD returns to renegotiation table; BMS suffers from partner’s silence. ...